5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 7.87▲ | 7.84▲ | 7.83▲ | 7.69▲ | 7.30▲ |
MA10 | 7.83▲ | 7.84▲ | 7.88▲ | 7.14▲ | 6.81▲ |
MA20 | 7.81▲ | 7.84▲ | 7.76▲ | 7.18▲ | 6.80▲ |
MA50 | 7.83▲ | 7.70▲ | 7.38▲ | 6.78▲ | 8.34▼ |
MA100 | 7.79▲ | 7.13▲ | 6.92▲ | 6.75▲ | N/A |
MA200 | 7.68▲ | 7.03▲ | 6.87▲ | 7.74▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.019▲ | -0.010▼ | -0.022▼ | 0.117▲ | 0.270▲ |
RSI | 59.468▲ | 60.474▲ | 62.742▲ | 65.882▲ | 53.429▲ |
STOCH | 79.796 | 46.190 | 48.908 | 88.303▲ | 54.191 |
WILL %R | 0.000▲ | -25.316 | -21.739▲ | -6.967▲ | -16.927▲ |
CCI | 149.626▲ | 31.908 | 51.058 | 109.716▲ | 126.879▲ |
Thursday, June 05, 2025 04:59 PM
PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company ...
|
Thursday, June 05, 2025 04:59 PM
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax ...
|
Wednesday, June 04, 2025 05:00 PM
ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 1,180,000 shares, a ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
03/07/25 | 7.95 | 8.065 | 7.645 | 7.96 | 374,623 |
02/07/25 | 7.80 | 8.13 | 7.71 | 7.76 | 207,124 |
01/07/25 | 7.83 | 7.83 | 7.41 | 7.66 | 402,268 |
30/06/25 | 7.53 | 8.06 | 7.52 | 7.65 | 487,212 |
27/06/25 | 7.24 | 7.59 | 7.24 | 7.40 | 241,782 |
26/06/25 | 7.04 | 7.24 | 6.8945 | 7.18 | 146,918 |
25/06/25 | 6.65 | 7.15 | 6.52 | 7.05 | 180,531 |
24/06/25 | 6.27 | 6.75 | 6.2001 | 6.65 | 212,776 |
23/06/25 | 5.99 | 6.16 | 5.69 | 6.11 | 239,576 |
20/06/25 | 6.18 | 6.19 | 5.8825 | 5.97 | 334,179 |
|
|
||||
|
|
||||
|
|